(Press-News.org) DOWNLOADABLE VIDEO
MIAMI, FLORIDA (EMBARGOED UNTIL MONDAY, DEC. 11, 2023 @ 7 P.M. ET) – In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of the treatment plan.
Study results will be released during an oral presentation at the 65th ASH Annual Meeting and Exposition, the American Society of Hematology’s conference taking place in San Diego, California, Dec. 9-12. The report has been identified by ASH as a clinically relevant abstract.
Mutations in several genes have been implicated in the development of acute myeloid leukemia, or AML, a type of cancer that starts in the blood-forming cells of bone marrow. About 30% of all cases result from mutations in a gene called FLT3 – FMS-like tyrosine kinase 3 – and the majority of these involve “internal tandem duplication,” or ITD. The new drug, quizartinib, specifically targets this FLT3-ITD mutation, which is found in about 25% of all AML cases and is associated with poor survival.
“In previous research, we showed that patients treated with quizartinib had improved survival compared with patients who didn’t receive the drug. This study further demonstrated that patients treated with quizartinib had better quality of life over time and that the side effects from the drug did not negatively affect the improved quality of life,” said Dr. Mikkael A. Sekeres, a Sylvester researcher, chief of the Division of Hematology, and senior author of the abstract presented at ASH. One focus of Sekeres’ research is AML in older adults.
Quizartinib was recently approved by the U.S. Food and Drug Administration to be used in combination with chemotherapy for the first and second phases of treatment – called induction and consolidation phases – for adult patients with newly diagnosed FLT3-ITD-positive AML. It also can be used alone as maintenance therapy and has been approved for similar applications in the European Union and Japan.
The current study, looking specifically at patient-reported quality-of-life outcomes – is a continuation – an exploratory endpoint – of findings coming from QuANTUM-First, a global, Phase 3 clinical trial that evaluated the safety and effectiveness of the drug, marketed as VANFLYTA by Daiichi Sankyo Inc.
“Not only did we find that patients treated with quizartinib lived longer, and they lived better, but those who went on to have a bone marrow transplant had particularly improved quality of life,” said Sekeres, who was a co-author of the QuANTUM-First findings reported earlier this year in The Lancet.
The current abstract’s first author, Dr. Esther Natalie Oliva, will present the findings. Oliva is a hematologist and researcher at Grande Ospedale Metropolitano Bianchi Melacrino in Reggio Calabria, Italy.
The authors said QuANTUM-First is the first study to explore the impact of an FLT3-inhibitor as first-line therapy on patient-reported outcomes. Patients treated with quizartinib who achieve complete remission remain in remission longer, continue treatment longer, and have better quality of life than those who do not receive the drug.
Sekeres said the research team plans to conduct additional studies combining quizartinib with different chemotherapy regimens used to treat patients who have FLT3-positive AML to see if it provides similar improvements in quantity and quality of life.
Authors: In addition to senior author Sekeres and first author Oliva, authors included Sudhir Unni, Daiichi Sankyo Inc., Basking Ridge, New Jersey; Francesco Cottone, Ph.D., Daiichi Sankyo Italia, Rome, Italy; Rohan Vashi, Pharm.D., Daiichi Sankyo Inc., Basking Ridge, New Jersey; Xiaocong Li, Ph.D., OPEN Health Evidence & Access, Bethesda, Maryland; and Dr. Jorge Cortes, Augusta University Medical Center, Georgia.
Funding: The study was funded by Daiichi Sankyo Inc.
Conflicts and disclosures: Sekeres serves on advisory boards for Bristol Myers Squibb, Kurome Therapeutics, and Novartis.
# # #
DOWNLOADABLE VIDEO
Funding: Funding information is available in the abstract.
Conflicts and disclosures: Sekeres serves on advisory boards for Bristol Myers Squibb, Kurome Therapeutics, and Novartis. Other disclosures are available in the abstract.
END
UNDER STRICT EMBARGO UNTIL 00:01 AM (UK TIME) ON TUESDAY 12TH DECEMBER 2023
A rare roofed theatre, markets, warehouses, a river port and other startling discoveries made by a Cambridge-led team of archaeologists challenge major assumptions about the decline of Roman Italy.
New findings from Interamna Lirenas, traditionally written off as a failed backwater in Central Italy, change our understanding of Roman history, its excavators believe.
Their thirteen-year study – published today in the edited volume Roman Urbanism in Italy ...
Living through a historic pandemic while handling the stress of the first year of college sent one-third of students in a new study into clinical depression. That’s double the percentage seen in previous years of the same study.
And while certain genetic factors appeared to shield first-year students in pre-pandemic years from depression, even students with these protective factors found themselves developing symptoms in the pandemic years.
In fact, much of the overall rise in student depression during the pandemic was among young women with this kind of “genetic resilience.”
But ...
On December 11, 2023, UC San Diego Health successfully completed the purchase of Alvarado Hospital Medical Center from Prime Healthcare. The acquisition of the 302-bed medical facility greatly expands the university’s growing network of clinics and hospitals to better serve patients with safe, timely and equitable access to high-quality health care.
“We are grateful to all the teams who contributed to this milestone merger with UC San Diego Health. Together, we start a new chapter to expand access to needed medical and surgical care in eastern ...
The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.
Anti-CD19 CAR T-cells with a CD28 co-stimulatory domain, such as axicabtagene ciloleucel and brexucabtagene autoleucel, are among the most effective CAR T-cell therapies for B-cell non-Hodgkin lymphomas but are associated with neurotoxicity (immune effector cell-associated neurotoxicity syndrome, ICANS) in around half of recipients, ...
The American Society of Anesthesiologists (ASA) strongly endorses H.R. 6683, legislation that would block a more than 3% Medicare payment cut scheduled to take effect on January 1, 2024. ASA supports the immediate passage of this legislation this year or early 2024, prior to full implementation of these destructive cuts.
“We commend these lawmakers for their leadership on preventing this Medicare payment cut and their efforts to ensure the viability of the nation’s physician practices,” said ASA President Ronald ...
Registrations are open to apply for the São Paulo School of Advanced Science on Quantum Materials, to be held on July 6-16, 2024, at the University of São Paulo’s Physics Institute in São Paulo City, Brazil. The School expects to select and fully support 100 graduate students and young researchers (50 from Brazil and 50 from abroad) to take part in short courses and talks focusing on fundamental, theoretical, and experimental aspects of quantum materials – a fertile ...
Like a shiny, round ornament ready to be placed in the perfect spot on a holiday tree, supernova remnant Cassiopeia A (Cas A) gleams in a new image from NASA’s James Webb Space Telescope. As part of the 2023 Holidays at the White House, First Lady of the United States Dr. Jill Biden debuted the first-ever White House Advent Calendar. To showcase the “Magic, Wonder, and Joy” of the holiday season, Dr. Biden and NASA are celebrating with this new image from Webb.
While all ...
In December 2022, NASA’s MAVEN (Mars Atmosphere and Volatile EvolutioN) mission observed the dramatic and unexpected “disappearance” of a stream of charged particles constantly emanating off the Sun, known as the solar wind. This was caused by a special type of solar event that was so powerful, it created a void in its wake as it traveled through the solar system.
Due to this event, MAVEN’s measurements at Mars showed that the number of particles making up the solar wind dropped significantly. Without the pressure of the solar wind, the Martian atmosphere and magnetosphere expanded by thousands of kilometers. MAVEN is the only asset currently at Mars able to ...
As presented at the Society for Risk Analysis 2023 Annual conference, Patrycja Sleboda from Baruch College – CUNY and her colleagues from the University of Southern California conducted a national food choice experiment to determine how people respond to labels such as “vegan” and “plant-based” compared to “healthy,” “sustainable,” or “healthy and sustainable.”
Research has shown that limiting meat and dairy intake and eating more fruit and vegetables reduces the risk of cardiovascular diseases, Type 2 diabetes, and cancer. Diets with less meat and dairy are also more environmentally ...
Embargoed for release until 5:00 p.m. ET on Monday 11 December 2023
Annals of Internal Medicine Tip Sheet
@Annalsofim
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
----------------------------
1. Group summarizes guidance for the prevention, ...
